Overview of MCP AL retard
| Property | Description |
|---|---|
| Active ingredient | Metoclopramide |
| Form | Sustained-release hard capsule (Retard) |
| Pharmacological class | Prokinetic agent, Miscellaneous antiemetic |
| Common use | Relieving nausea, vomiting, and gastric motility issues |
| Origin | Synthetic compound |
What is the Composition and Class of MCP AL retard?
MCP AL retard is a prescription-only pharmaceutical preparation whose sole active ingredient is the synthetic compound Metoclopramide. Pharmacologically, Metoclopramide is classified as a prokinetic agent and a miscellaneous antiemetic. This classification means the medicine is designed to enhance the physical movement, or motility, within the digestive tract, a function intended for promoting the transit of contents through the upper digestive system. Metoclopramide is primarily a dopamine receptor antagonist, a core mechanism that facilitates both improved digestive function and control over the urge to vomit.
Why is it a "Retard" Sustained-Release Capsule?
The term "retard" defines this specific oral formulation as a sustained-release hard capsule, which is a specialized design intended to deliver the Metoclopramide slowly into the body over an extended period. This mechanism ensures prolonged therapeutic action, a distinguishing feature compared to immediate-release tablets where the active ingredient is absorbed quickly. The sustained-release characteristic is achieved through specific excipients that control the drug’s dissolution rate, maintaining a stable, effective concentration of the medicine in the bloodstream. This stable delivery over time is crucial for patients requiring consistent symptom management throughout the day.
What is the General Purpose of This Prokinetic Agent?
The general purpose of MCP AL retard is to leverage the dual physiological action of Metoclopramide: enhancing gastric movement and suppressing the urge to feel sick. It functions by promoting rhythmic contractions (peristalsis) of the stomach, accelerating the rate of gastric emptying. Concurrently, its anti-emetic effect works centrally by modulating signals that trigger the reflexes of nausea and vomiting. These combined mechanisms allow the medication to generally help relieve common discomforts associated with irregular or slow movement in the upper digestive system, often seen in conditions like diabetic gastroparesis, by normalizing transit and suppressing the feeling of sickness.
Regulatory References

